PCAC July 2026 Meeting Tracker: Every Peptide Under FDA Review

On 16 April 2026, the FDA published a Federal Register notice confirming that its Pharmacy Compounding Advisory Committee will convene on 23-24 July 2026 at the FDA’s White Oak Campus in Silver Spring, Maryland. The two-day session will be open to the public both in person and via teleconference.

The committee will evaluate whether seven peptide bulk drug substances should be added to the Section 503A Bulk Drug Substances List. Inclusion on that list would allow licensed 503A pharmacies to prepare these peptides for individual patients with valid prescriptions, and 503B outsourcing facilities to compound them at scale. These seven peptides were among 12 removed from the FDA’s restricted Category 2 list in April 2026 following the reclassification process tracked in our reclassification tracker. For context on the difference between Category 1 and Category 2, see our explainer.

Each peptide is being evaluated for a specific medical use. The FDA will assess physical and chemical characterisation, safety profile, evidence of effectiveness, and historical use in compounding. Nominators will present their supporting data, and the committee will vote on each substance individually.

Day	Peptide	Indication Under Review	Key FDA Concern (2023)
1	BPC-157	Ulcerative colitis	Impurity and API characterisation issues; no completed human trials
1	KPV	Wound healing, inflammatory conditions	Absence of human exposure data
1	TB-500	Wound healing	Limited human safety data
1	MOTs-C	Obesity, osteoporosis	Immunogenicity risk; impurity concerns
2	Emideltide (DSIP)	Opioid withdrawal, chronic insomnia, narcolepsy	CNS-active; blood-brain barrier interaction
2	Semax	Cerebral ischaemia, migraine, trigeminal neuralgia	CNS-active; evidence primarily from Russian-language studies
2	Epitalon	Not specified at same detail level	Limited human evidence; telomerase claims unverified

BPC-157 (free base / acetate)

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective gastric protein. The FDA is assessing it specifically for ulcerative colitis. It is the highest-profile peptide in this review – frequently cited by podcasters, biohacking communities and clinicians – but also carries the most scrutiny. The FDA’s 2023 safety assessment flagged impurity concerns, API characterisation issues, and the absence of completed human clinical trials. The evidence base consists entirely of preclinical rodent studies, which, while extensive (covering tendon, ligament, muscle, gut and bone models), has not been replicated in controlled human settings. This gap between community enthusiasm and clinical evidence will be central to the committee’s deliberation. For a full breakdown, see our BPC-157 research guide.

KPV (free base / acetate)

KPV is a tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH) being considered for tissue repair and inflammatory conditions. It has demonstrated anti-inflammatory properties in preclinical models, but the FDA’s primary concern is stark: there is no published human exposure data for KPV at all. Unlike BPC-157, which at least has decades of preclinical literature, KPV’s evidence base is comparatively thin. Whether the nominator can address this gap in their presentation will likely determine the outcome.

TB-500 (free base / acetate)

TB-500, a synthetic fragment of Thymosin Beta-4, is on the agenda for wound healing. It has an established preclinical evidence base around cellular migration, tissue regeneration and cytoskeletal organisation. TB-500 is frequently discussed alongside BPC-157 in online communities, and a favourable outcome for both would carry outsized significance for the regenerative peptide space. For more detail, see our TB-500 research guide.

MOTs-C (free base / acetate)

MOTs-C (Mitochondrial Open Reading Frame of the 12S rRNA Type-C) is being assessed for obesity and osteoporosis. It is a mitochondrial-derived peptide involved in metabolic regulation and exercise-mimicking pathways. The FDA raised two specific concerns in 2023: significant immunogenicity risk for certain routes of administration, and impurity and API characterisation issues similar to those flagged for BPC-157. Of the four Day 1 peptides, MOTs-C may face the hardest scrutiny given the immunogenicity question – a concern that contributed to negative votes on other peptides at the October 2024 PCAC session.

The second day covers three peptides with neurological and neuroendocrine applications. These face additional scrutiny because they interact with central nervous system pathways and/or cross the blood-brain barrier.

Emideltide / DSIP (free base / acetate)

Emideltide, also known as delta sleep-inducing peptide (DSIP), is being assessed for opioid withdrawal, chronic insomnia and narcolepsy. It is a nonapeptide originally isolated from rabbit brain tissue in 1977 by Swiss researchers Schoenenberger and Monnier. Its inclusion carries particular political weight given the ongoing opioid crisis – a favourable outcome could position compounded DSIP as a non-opioid tool in withdrawal management, which aligns with broader HHS priorities. However, DSIP’s mechanism of action remains incompletely understood, and its sleep-inducing effects have produced inconsistent results across the limited studies available.

Semax (free base / acetate)

Semax is a synthetic heptapeptide analogue of ACTH(4-10) being evaluated for cerebral ischaemia, migraine and trigeminal neuralgia. Of the seven peptides in this review, Semax arguably has the strongest existing clinical framework: it has been approved and clinically used in Russia since the 1990s for stroke recovery and cognitive support, marketed under the brand name Semax by the Institute of Molecular Genetics. The challenge is that much of this evidence comes from Russian-language journals and has not been replicated in Western clinical trial infrastructure. Whether the PCAC considers Russian regulatory approval and clinical usage as meaningful precedent will be a significant variable.

Epitalon (free base / acetate)

Epitalon (also spelled Epithalon) is a synthetic tetrapeptide based on the pineal gland’s epithalamin, studied primarily for its effects on telomerase activation and circadian rhythm regulation. The Federal Register notice does not detail the specific indication at the same level as the other six peptides, which itself may be telling. Human evidence is limited, and the telomerase claims that dominate online discussion have not been verified in controlled clinical settings. Epitalon may be the hardest sell of the seven given this evidence gap.

Most coverage of the July 2026 meeting treats a favourable outcome as likely, given the political momentum behind reclassification. That framing overlooks what happened the last time the PCAC reviewed peptides. At the 29 October 2024 session, the committee voted against recommending ipamorelin, ibutamoren mesylate and kisspeptin-10 for the Bulks List. At the 4 December 2024 session, the same structural outcome occurred: the PCAC voted against including CJC-1295, thymosin alpha-1 and AOD-9604. In both cases, the FDA had recommended rejection, citing insufficient human safety data, endocrine concerns and a lack of reproducible efficacy evidence.

The FDA has announced a second PCAC session before the end of February 2027 to review five additional peptides. A public docket for this meeting has not yet been opened.

• GHK-Cu (injectable routes) – copper-binding tripeptide studied for tissue repair and skin regeneration. Non-injectable GHK-Cu is on a separate evaluation track.
• Melanotan II – synthetic alpha-MSH analogue. Carries the most regulatory baggage in this cohort, with safety warnings from the FDA, MHRA and TGA.
• Cathelicidin (LL-37) – antimicrobial peptide of the innate immune system, studied for wound healing and anti-infective properties.
• Dihexa acetate – hexapeptide analogue of angiotensin IV, studied in preclinical models for cognitive enhancement.
• PEG-MGF – pegylated splice variant of IGF-1, studied for muscle repair and hypertrophy.

Even a positive recommendation is a procedural starting point, not a finish line. Legal analysts at Foley & Lardner and the FDA Law Blog have emphasised that without formal notice-and-comment rulemaking, any direct reclassification would face legal challenge. Here is the realistic path:

• Now through 9 July 2026: Written comments submitted to the public docket via regulations.gov by this date will be provided directly to the committee.
• 23-24 July 2026: PCAC meets and votes on each peptide individually.
• Late 2026 (estimated): If the committee recommends inclusion, the FDA conducts internal review and publishes a final rule. This rulemaking process typically takes several months.
• Late 2026 to Q1 2027 (estimated): Once the rule is published, licensed compounders can source bulk peptide material and begin filling prescriptions. Supply chains, quality testing and inventory will need to be established. Under Section 503A, the bulk API must be manufactured at an FDA-registered drug establishment and accompanied by a Certificate of Analysis. Whether the current peptide supply chain – much of it originating from Chinese manufacturers without FDA registration – can meet these standards at scale is an open question.

The public docket (FDA-2025-N-6895) accepts written submissions via regulations.gov or by mail. Comments received by 9 July 2026 will be provided directly to the committee members. The docket stays open until 22 July, but later submissions may not reach the committee in time.

Anyone wishing to present orally must notify the FDA contact (Takyiah Stevenson, PharmD, PCAC@fda.hhs.gov, 240-402-2507) by 30 June 2026. Time per presentation may be limited, and if demand exceeds available slots the FDA may conduct a lottery.

• These peptides are not FDA-approved drugs. Even if added to the Bulks List, they have not gone through the clinical trial process required for drug approval. They would be available as compounded preparations under physician supervision only.
• They will not be available over the counter. A valid prescription from a licensed provider is required.
• “Research use only” grey-market vendors are not affected. The PCAC process governs licensed pharmacies under the 503A/503B frameworks, not unregulated online sellers.
• The broader legal status of peptides in the US remains multi-layered. This meeting addresses one specific pathway.

• 30 June 2026 – Deadline to register for oral presentations
• 9 July 2026 – Deadline for written comments to reach the committee
• 22 July 2026 – Docket closes
• 23 July 2026 – Day 1: BPC-157, KPV, TB-500, MOTs-C
• 24 July 2026 – Day 2: Emideltide (DSIP), Semax, Epitalon
• Before end of February 2027 – Second session: GHK-Cu, Melanotan II, LL-37, Dihexa, PEG-MGF